Wild-Type JCV VP1 Immunogen Broad Neutralizing Antibody Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for preventing or inhibiting JC polyomavirus (JCV)-associated progressive multifocal leukoencephalopathy (PML), particularly in immunosuppressed individuals, as existing treatments are either ineffective or lead to irreversible CNS damage, and there is a need for compositions that can elicit an immune response against multiple JCV genotypes, including those with VP1 mutations associated with PML.
Innovation Solution
Administration of a monovalent immunogenic composition based on wild-type (WT) JCV VP1 polypeptides, such as those from urine-derived JCV genotypes, elicits a neutralizing antibody response against multiple JCV genotypes, including those with VP1 mutations associated with PML, with WT-based compositions being more effective than PML-derived mutant VP1 polypeptide compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunogenic compositions based on PML-derived mutant JCV VP1 polypeptides are used, then the composition is designed to target PML-associated mutations, but the composition is less effective for eliciting neutralizing antibody responses
Solution Approach 1:
Instead of using PML-derived mutant VP1 polypeptides as the immunogen, the invention inverts the approach by using wild-type (WT) JCV VP1 polypeptides as the immunogenic composition. This inversion unexpectedly elicits broadly cross-neutralizing antibody responses that are effective against multiple JCV genotypes including those with PML-associated mutations, thereby resolving the contradiction between targeting specific mutations and achieving broad protection.
Solution Approach 2:
The WT JCV VP1 polypeptide immunogenic composition achieves universality by eliciting neutralizing antibodies that recognize and neutralize multiple JCV genotypes (genotypes 1-8) and PML-associated mutant strains. A single immunogen based on WT VP1 provides multi-functional protection across diverse viral variants, eliminating the need for genotype-specific or multivalent vaccines.
2Adaptability or versatility
If monovalent WT JCV VP1 polypeptide compositions are administered, then broadly cross-neutralizing antibody responses are elicited against multiple JCV genotypes, but the complexity of developing and producing multiple genotype-specific compositions is avoided
Solution Approach 1:
The invention employs a monovalent immunogenic composition based on WT JCV VP1 polypeptide that universally protects against multiple JCV genotypes (1-8) and PML-associated mutants. This single-component vaccine achieves multi-functional activity, eliminating the need for complex multivalent formulations containing multiple genotype-specific antigens, thereby simplifying development, production, and implementation.
3Reliability
If existing treatments for JCV-induced PML are used, then treatment options are limited, but irreversible CNS damage occurs and treatments are ineffective
Solution Approach 1:
The invention applies preliminary action by administering the WT JCV VP1 polypeptide immunogenic composition before PML disease onset or at early stages. This preventive or early therapeutic vaccination elicits neutralizing antibody responses that can inhibit viral replication and prevent progression to irreversible CNS damage, whereas existing treatments are ineffective once established PML occurs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of WT JCV VP1 polypeptide compositions induces a broadly cross-neutralizing antibody response, effectively inhibiting JCV infection and reducing the risk of PML development in vulnerable subjects, as demonstrated by increased neutralizing antibody titers and stabilization of PML lesions in treated patients.
Implementation Method 1
administration of an immunogenic composition with a polypeptide (such as a VP1 polypeptide) from a single WT JCV isolate elicits an immune response (for example, a neutralizing antibody response) against multiple JCV genotypes
Implementation Method 2
eliciting an immune response (for example, a neutralizing antibody response) against multiple JCV genotypes, including JCV genotypes with VP1 polypeptides including one or more mutations associated with PML
Data Source
AI summary
Methods of eliciting an immune response to a JC polyomavirus (JCV) by administering an effective amount of an immunogenic composition including an isolated JCV VP1 polypeptide or a nucleic acid encoding the VP1 polypeptide to a subject are provided. VP1 polypeptides and immunogenic compositions suitable for use in the methods are provided, including JCV genotype 2 VP1 polypeptides and/or JCV genotype 3 polypeptides. Methods of identifying a subject at risk of developing progressive multifocal leukoencephalopathy (PML) are also provided. In some embodiments, the methods include obtaining a biological sample from a subject, detecting presence or absence of JCV neutralizing antibodies in the sample from the subject, and identifying that the subject is at risk of developing PML if there is an absence of detectable JCV neutralizing antibodies in the sample from the subject.